Drug recall · January 29, 2020
Ranitidine recall
Why: CGMP Deviations: Presence of NDMA impurity detected in product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J. Harkins Company, Inc. dba Pharma Pac Grover Beach, CA 93433 NDC #s: 52959-0502-07, 52959-0502-14, 52959-0502-20, 52959-0502-30 and 52959-0502-60
- Lots / codes
Lot #s: RAN63KG Exp. 05/20, RAN64KG Exp. 10/20, RAN65KG Exp. 11/20, RAN66KG Exp. 05/21
- Quantity
- 7,212 tablets
- Company
- H J Harkins Company Inc dba Pharma Pac, Grover Beach, CA
- Distribution
- Distributed to Physicians in the following states: CA, FL, NC, and SC.
- Initiated
- January 6, 2020 · Voluntary: Firm initiated
- Classified
- January 20, 2020
- Reported
- January 29, 2020
- Ended
- December 15, 2023
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.